The Wall Street Journal’s (WSJ) Brian Gormley recently sat down with Ovation’s Curt Medeiros and Barry Wark to learn how Ovation is thinking differently when it comes to capturing genomic data for use in research and development. Ovation’s innovative model and diverse genomic data linked with phenotypic data at scale captured the attention of the WSJ. Specifically, Gormley highlights Ovation’s >1.3 million specimens from 453,000 consented patients which can be used for research purposes.
“It’s about helping drug discovery be faster, be more efficient,” said S. Somasegar, a managing director with Madrona. “One key component is access to samples and patient data, which is what Ovation is delivering.”
Ovation recently raised $12 million in Series B add-on funding to expand its research network and genomic data business.
Read the article to learn more about how Ovation is delivering genomic data to increase speed-to-market for drug discovery.